Sermorelin: Research & Evidence
Established EvidencePublished research, clinical trial data, and evidence grading for Sermorelin across studied indications.
Back to Sermorelin overviewResearch Summary
Sermorelin was FDA-approved in 1997 (brand name Geref) for pediatric growth hormone deficiency based on Phase 3 data showing increased GH and height velocity in 164 children. It was discontinued by the manufacturer in 2008 for commercial reasons — not safety concerns — and is now available only as a compounded medication. Approximately 50+ human studies exist, primarily in pediatric GHD. Adult 'anti-aging' use is based on limited observational data showing IGF-1 increases but no RCT evidence for body composition, strength, or longevity outcomes.
Evidence by Indication (3 indications)
| Indication | Tier | Trials | Summary |
|---|---|---|---|
| GH stimulation testing | Tier A | 5 | Validated diagnostic tool for GH deficiency assessment |
| GH deficiency | Tier B | 12 | Well-established GH secretagogue with Phase III data; FDA-approved 1997-2008 for pediatric GHD |
| Anti-aging | Tier C | 4 | Limited controlled data for anti-aging indications; IGF-1 increases observed but outcomes unproven |
Graded using our evidence tier methodology.
Citations (4 sources)
- 1. Phase 3 trial of sermorelin for pediatric growth hormone deficiency Clinical Trial
Various (1997), Journal of Clinical Endocrinology & Metabolism
- 2. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency Review
(1999), BioDrugs
- 3. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy Study
Geref International Study Group (1996), Journal of Clinical Endocrinology & Metabolism
- 4. Macimorelin (AEZS-130)-stimulated growth hormone (GH) test: validation of a novel oral stimulation test for the diagnosis of adult GH deficiency Study
(2013), Journal of Clinical Endocrinology & Metabolism